What is STRATEOS?
STRATEOS is a pioneering force in the life sciences sector, dedicated to accelerating scientific discovery through its advanced Cloud Lab Automation-as-a-Service Platform. The company leverages data, computation, automation, and high-throughput robotics to fundamentally transform how research is conducted. By enabling scientists to more efficiently and reproducibly design, execute, and analyze experiments, STRATEOS aims to drive new knowledge creation and faster breakthroughs. Its mission is to build a future where data and automation are central to scientific advancement, fostering a new era of discovery in the life sciences.
How much funding has STRATEOS raised?
STRATEOS has raised a total of $64.6M across 2 funding rounds:
Series A
$8.5M
Series B
$56.1M
Series A (2015): $8.5M with participation from Y Combinator, Silicon Valley Bank, AME Cloud Ventures, MITS Fund, Wei Guo, UpHonest Capital, Holtzbrinck Digital, Paul Buchheit, IA Ventures, and DCVC
Series B (2021): $56.1M led by Ally Bridge Group, Lux Capital, DCVC Management, Lilly, and Black Diamond Ventures
Key Investors in STRATEOS
Ally Bridge Group
Ally Bridge Group is a global healthcare investment management firm specializing in high-impact life science innovation, managing over $6 billion in transactions since its inception in 2013. The firm operates from offices in New York and Hong Kong, focusing on both private equity and public equity strategies across the healthcare sector.
Lux Capital
Lux Capital is a New York based venture capital firm that raises dedicated funds to invest in earlystage and growthstage companies at the intersection of science and technology, backing founders in frontier areas such as AI, robotics, space, defense, biotechnology, and advanced materials from seed through IPO or acquisition.
DCVC Management
DCVC is a deep tech venture capital firm that invests in entrepreneurs tackling some of the world's most challenging problems. The company focuses on leveraging artificial intelligence to unlock potential across various sectors, including energy, biotechnology, and agriculture.
What's next for STRATEOS?
The substantial enterprise-level funding and recent strategic investment position STRATEOS for accelerated growth and expanded market penetration. With a focus on enhancing its lab automation software and remote access capabilities, the company is poised to further solidify its leadership in the life science discovery ecosystem. Future developments are likely to involve scaling its platform, forging new strategic partnerships, and continuing to innovate in areas such as AI-driven experimental design and robotic process automation. This strategic financing will empower STRATEOS to capitalize on emerging opportunities and drive significant advancements in scientific research.
See full STRATEOS company page
